Code intelligence

FDA-NDA215014 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA215014.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: EMPAVELI (PEGCETACOPLAN) — Type 1 - New Molecular Entity

Policy FDA-NDA215014 · Hematology

High

Empaveli (pegcetacoplan) was approved May 14, 2021 as a subcutaneous solution for a rare condition under orphan drug designation, billing under Medicare Part B. As a subcutaneous injectable administer

View alert

Audit documentation

Building an audit file that includes FDA-NDA215014?

The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Hematology audit pack — $349One-time purchase · not a subscription